Treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir in chronic hepatitis C genotype 2k/1b.

Abstract

Aim: Hepatitis C virus (HCV) infection is one of the most prevalent etiologies for liver cirrhosis and hepatocellular carcinoma. As a result of being highly heterogeneous, HCV has seven confirmed major genotypes and 67 confirmed subtypes.  The importance of correctly determining each genotype and its subtype is dependent on choosing the relevant combination and duration of anti-viral treatment. The recombinant HCV genotype 2k/1b was first detailed in St. Petersburg in 2002 among intravenous drug users. Treatment of HCV 2k/1b patients with sofosbuvir and ribavirin resulted in a lowered sustained virologicresponse rate (SVR). The high efficacy of the 3D regimen (ombitasvir/paritaprevir/ritonavir and dasabuvir) has been proven for genotype1b population; however it has not been evaluated for patients with 2k/1b HCV genotype.

The aim of this study was to evaluate the efficacy and safety of a twelve week treatment for patients infected with HCV 2k/1b utilizing the 3D regimin - ombitasvir/paritaprevir/ritonavir and dasabuvir (3D).

Materials and Methods: This is an open-label, single arm study. Seven patients received ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily as well as dasabuvir 250 mg twice daily for twelve weeks.

Results: Six patients achieved a SVR without significant adverse events. One patient discontinued the treatment at week four due to headaches and vomiting.

Conclusions: This study demonstrates the high efficacy and safety of a twelve week treatment of ombitasvir/ paritaprevir/ritonavir and dasabuvir (3D) for adult patients with HCV 2k/1b.

ClincialTrials.gov, number NCT03050905